Search

Displaying results 1521 - 1530 of 7687 in total
  1. Drug

    Rifamycin

    go.drugbank.com/drugs/DB11753
    ApprovedInvestigationalWithdrawn

    [L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801] … [A39986] Rifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease

  2. Drug

    Prednisolone phosphate

    go.drugbank.com/drugs/DB14631
    ApprovedInvestigationalVet approved

    [A187463] Prednisolone phosphate was granted FDA Approval on 19 December 1973.[L14144]

  3. Drug

    Arimoclomol

    go.drugbank.com/drugs/DB05025
    Approved

    [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).

  4. Target

    Frataxin, mitochondrial

    go.drugbank.com/bio_entities/BE0008991
    TargetHumans

    Functions as an activator of persulfide transfer to the scaffoding protein ISCU as component of the core iron-sulfur cluster (ISC) assembly complex and participates to the [2Fe-2S] cluster assembly (PubMed:12785837, PubMed:24971490). Acc...

    Synonyms: FRDA
  5. Drug

    Norethisterone

    go.drugbank.com/drugs/DB00717
    ApprovedInvestigational

    L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an

  6. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil has received Orphan Drug status from the FDA for the treatment of hepatocellular cancer in combination with fluoropyrimidines (including 5-FU). … Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.

  7. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … In May 2023, epcoritamab was approved by the FDA under accelerated approval for the treatment of relapsed or refractory DLBCL.

  8. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    [L49246] In January 2024, exagamglogene autotemcel received an additional FDA approval for the treatment of transfusion-dependent β-thalassemia. … It was approved by the FDA in December 2023 for the treatment of patients with SCD with recurrent vaso-occlusive crises.

  9. Drug

    Temazepam

    go.drugbank.com/drugs/DB00231
    Approved

    Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant ...

  10. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    [L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770] … Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager.

    Synonyms: ANTIBODY; BISPECIFIC GAMMA4 HEAVY CHAIN HUMANIZED AN, IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL